nykek5i 发表于 2024-5-28 14:03:06

2024值得关注的5种癌症疫苗！

<img src="https://mmbiz.qpic.cn/mmbiz_png/pHzHVM2oJO2I0a8vLzaFwgPvCSRSGUE0V4HDC4vP6Uv65Ck7UY2fmBQK5GrcicQQBsjLG82JtRNBSZNcIbqspSQ/640?wx_fmt=png&amp;from=appmsg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/pHzHVM2oJO2I0a8vLzaFwgPvCSRSGUE0qPItJUibJTwRmT9Xt5oAicj7bnAm1MqKBeOTryBoavcj9aDGvAOnuJdQ/640?wx_fmt=png&amp;from=appmsg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;">
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">作者：Rainbow</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">导读</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">&nbsp;01&nbsp;</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">几种癌症疫苗候选<span style="color: black;">药品</span>正在<span style="color: black;">经过</span>临床<span style="color: black;">实验</span>，并取得了有<span style="color: black;">期盼</span>的结果。与旨在预防<span style="color: black;">疾患</span><span style="color: black;">出现</span>的传统疫苗不同，治疗性癌症疫苗<span style="color: black;">能够</span>训练<span style="color: black;">病人</span>的免疫系统，使T细胞巡视<span style="color: black;">身体</span>的癌细胞并摧毁它们。本文介绍了五种<span style="color: black;">日前</span><span style="color: black;">处在</span>临床<span style="color: black;">实验</span><span style="color: black;">周期</span>的癌症疫苗。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">V940/mRNA-4157</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">&nbsp;02&nbsp;</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">V940/mRNA-4157由Moderna和默沙东<span style="color: black;">机构</span><span style="color: black;">一起</span><span style="color: black;">开发</span>，<span style="color: black;">日前</span><span style="color: black;">处在</span>3期临床<span style="color: black;">实验</span><span style="color: black;">周期</span>，是一款基于新抗原和mRNA技术的个体化肿瘤疫苗。V940/mRNA-4157由单个合成的mRNA<span style="color: black;">构成</span>，<span style="color: black;">能够</span>编码来自<span style="color: black;">病人</span>独特遗传癌症标记的最多34个新抗原。当这些新抗原被翻译时，会触发T细胞的激活和增殖，这些T细胞会监测<span style="color: black;">身体</span>表达这些新抗原的癌细胞。该疫苗将与免疫<span style="color: black;">检测</span>点<span style="color: black;">控制</span>剂Keytruda（pembrolizumab）<span style="color: black;">一块</span><span style="color: black;">运用</span>，适用于经手术切除高<span style="color: black;">危害</span>黑色素瘤（IIB-IV期）<span style="color: black;">病人</span>。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;">autogene cevumeran</span></strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">&nbsp;03&nbsp;</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">autogene cevumeran由BioNTech和Genentech<span style="color: black;">机构</span><span style="color: black;">一起</span><span style="color: black;">开发</span>，<span style="color: black;">日前</span><span style="color: black;">处在</span>2期临床<span style="color: black;">实验</span><span style="color: black;">周期</span>。该疫苗与免疫<span style="color: black;">检测</span>点<span style="color: black;">控制</span>剂atezolizumab一同<span style="color: black;">运用</span>，可为不同<span style="color: black;">病人</span>量身定制。该疫苗<span style="color: black;">经过</span>mRNA表达PDAC<span style="color: black;">病人</span>的20种新抗原，<span style="color: black;">运用</span>LNP进行静脉注射给药。在手术切除后的PDAC<span style="color: black;">病人</span>中，与化疗和免疫<span style="color: black;">检测</span>点疗法联用时，该mRNA疫苗有<span style="color: black;">潜能</span>地延缓了PDAC<span style="color: black;">病人</span>的复发。该疫苗适用于胰腺导管腺癌<span style="color: black;">病人</span>。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">TG4050</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">&nbsp;04&nbsp;</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">TG4050由Transgene和NEC<span style="color: black;">机构</span><span style="color: black;">一起</span><span style="color: black;">开发</span>，<span style="color: black;">日前</span><span style="color: black;">处在</span>1期临床<span style="color: black;">实验</span><span style="color: black;">周期</span>。TG4050旨在刺激<span style="color: black;">病人</span>的免疫系统，以诱导T细胞反应，该反应能够基于其<span style="color: black;">自己</span>的新抗原识别和破坏肿瘤细胞。这种个性化的免疫疗法是为每位<span style="color: black;">病人</span><span style="color: black;">研发</span>和生产的。该疫苗适用于卵巢癌和HPV阴性头颈癌<span style="color: black;">病人</span>。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">Tedopi</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">05</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Tedopi由OSE Immunotherapeutics<span style="color: black;">机构</span><span style="color: black;">开发</span>，<span style="color: black;">日前</span><span style="color: black;">处在</span>2期临床<span style="color: black;">实验</span><span style="color: black;">周期</span>。该疫苗是一种抗原肽混合物，旨在激活抗肿瘤T细胞。这些抗原肽被<span style="color: black;">选取</span>是<span style="color: black;">由于</span>它们在<span style="color: black;">身患</span>NSCLC和HLA-A2表型的<span style="color: black;">病人</span>中<span style="color: black;">平常</span>表达。该疫苗适用于晚期非小细胞肺癌、胰腺导管腺癌和复发性卵巢癌<span style="color: black;">病人</span>。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">VB10.16</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">06</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">VB10.16由Nykode Therapeutics<span style="color: black;">机构</span><span style="color: black;">开发</span>，<span style="color: black;">日前</span><span style="color: black;">处在</span>2期临床<span style="color: black;">实验</span><span style="color: black;">周期</span>。VB10.16是一种基于质粒DNA的疫苗，编码了一个三部分的Vaccibody。其中三个单位之一是最多<span style="color: black;">包括</span>20个新抗原的集合体，另一个是针对抗原呈递细胞（APC）的靶向单元。<span style="color: black;">按照</span>吸引的APC类型，疫苗<span style="color: black;">能够</span>激活杀死携带新抗原的细胞的T细胞或产生针对携带新抗原的细胞的抗体的B细胞。该疫苗适用于HPV16阳性宫颈癌和HPV16阳性头颈部鳞状细胞癌<span style="color: black;">病人</span>。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">结语</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">&nbsp;07&nbsp;</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">个性化医学的<span style="color: black;">发展</span>使得测序<span style="color: black;">病人</span>基因组、提取独特的癌症标志并制备编码这些新抗原的疫苗变得更加容易和经济实惠。随着科学技术<span style="color: black;">持续</span>发展，癌症疫苗有望在<span style="color: black;">将来</span>发展出更加个性化、有效的治疗<span style="color: black;">办法</span>，为癌症<span style="color: black;">病人</span>带来<span style="color: black;">更加多</span><span style="color: black;">期盼</span>。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">参考资料：</p>

    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">https://www.biospace.com/article/5-cancer-vaccines-to-watch-in-2024/</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">注：本文旨在介绍医学<span style="color: black;">科研</span><span style="color: black;">发展</span>，<span style="color: black;">不可</span><span style="color: black;">做为</span>治疗<span style="color: black;">方法</span>参考。如需<span style="color: black;">得到</span>健康<span style="color: black;">指点</span>，请至正规医院就诊。</p>
    <img src="https://mmbiz.qpic.cn/mmbiz_png/pHzHVM2oJO2I0a8vLzaFwgPvCSRSGUE0z4gFl8AfKX7rPYdUmZ92xiapsLic7icZVnvGUTwnjHNYgV4lBoKdKxyWQ/640?wx_fmt=png&amp;from=appmsg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;">
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">热门·直播/活动</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;">�</a>� 北京｜12月19日-20日</p>
    <a style="color: black;">
      <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">▶第四届单细胞测序技术应用研讨会暨单细胞&amp;空间组学研讨会（日程稍后<span style="color: black;">颁布</span>）</p>
    </a>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">点击对应文字 查看详情</p>




明月几时有 发表于 2024-9-8 08:16:20

你的见解真是独到，让我受益匪浅。

听听海 发表于 5 天前

你的见解独到，让我受益匪浅，非常感谢。
页: [1]
查看完整版本: 2024值得关注的5种癌症疫苗！